The novel treatment consists of a single shot which is made of special proteins called antibodies that bind to the site at ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

Sneezing, fever, chills, vomiting, coughing — it’s not just one virus wreaking havoc this winter; it’s a combination of four ...

IT’S that time of year again when we’re seemingly greeted with a new cough, sneeze or sniffle every week. But as we beat one ...

The UK Health Security Agency (UKHSA) has issued a new warning this morning after a range of winter bugs started spreading ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...

Traditionally, the microbiologic diagnosis of RSV has been based on moderate to complex techniques performed in a laboratory (cell culture, nucleic acid amplification and immunofluorescence assays ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...